Year 2020 / Volume 112 / Number 7
Original
Recapture of patients with an incomplete diagnosis of hepatitis C virus infection

525-531

DOI: 10.17235/reed.2020.6944/2020

Cristina Burgui, Carmen Martín, Regina Juanbeltz, Ramón San Miguel, Iván Martínez-Baz, José Manuel Zozaya, Jesús Castilla,

Abstract
Background: hepatitis C virus (HCV) antibody tests have been performed since the 90s, although HCV-RNA (viral load) determination was not always performed. Some of these patients may be actively infected and not be aware of it. Here, we describe a procedure to capture these subjects and complete their diagnosis. Methods: the historical laboratory results of Navarra were reviewed and individuals who were positive for antibodies against HCV (anti-HCV) and had not undergone HCV-RNA testing were identified. In September 2018, each general practitioner (GP) was informed about their patients and given precise instructions for completing the diagnosis. The procedure was assessed until December 2019. Results: two hundred and eighty-nine anti-HCV positive patients were detected for whom active infection had not been discarded. Two were HIV-positive and six had already died. GPs were asked to assess the remaining 281 subjects. By the end of 2019, a new blood test had been performed in 187 (67 %) patients, 5 % decided not to do it, 4 % were living outside of Navarra, 3 % could not be contacted and the GP considered that it was not justified in 2 % of cases. Thus, 19 % remained to be contacted. From the 187 assessed patients, active infection was confirmed in 52 (28 %) individuals, 40 % were false positives and HCV-RNA was undetectable in 31 %. Regarding the 52 actively infected subjects, 34 had already initiated antiviral therapy and three were hospitalized due to decompensated cirrhosis, from which one patient died. Conclusions: the strategy to recapture individuals with an incomplete HCV infection diagnosis was effective to detect active infections and subsequent initiation of antiviral therapy.
Share Button
New comment
Comments
No comments for this article
References
1. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Geneva: World Health Organization, 2016. [Accessed 10 Feb 2020]. Available from: https://apps.who.int/iris/bitstream/handle/10665/246177/WHO-HIV-2016.06-eng.pdf.
2. Juanbeltz R, Zozaya JM, Repáraz J, et al. Effectiveness of second-generation direct-acting antivirals in chronic hepatitis C. An Sist Sanit Navar 2017; 40(1): 57-66. DOI: 10.23938/ASSN.0006.
3. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483-93. DOI: 10.1056/NEJMoa1316366.
4. Asselah T, Boyer N, Saadoun D, at al. Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspective. Liver Int 2016; 36 Suppl 1: 47-57. DOI: 10.1111/liv.13027
5. Chung RT, Baumert TF. Curing chronic Hepatitis C-The arc of a medical triumph. N Engl J Med 2014; 370: 1576-78. DOI: 10.1056/NEJMp1400986
6. Lange CM, Jacobson IM, Rice CM, et al. Emerging therapies for the treatment of hepatitis C. EMBO Mol Med 2014; 6: 4-15. DOI: 10.1002/emmm.201303131
7. Lam BP, Jeffers T, Younoszai Z, et al. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol 2015; 8: 298-312. DOI: 10.1177/1756283X15587481
8. Castilla J, Pollán M, López-Abente G. The AIDS epidemic among Spanish drug users: A birth-cohort associated phenomenon. Am J Public Health 1997; 87: 770-4. DOI: 10.2105/ajph.87.5.770
9. García Comas L, Ordobás Gavín M, Sanz Moreno JC, et al. Prevalence of hepatitis C antibodies in the population aged 16–80 years in the Community of Madrid 2008–2009. J Med Virol 2015; 87: 1697-701. DOI: 10.1002/jmv.24219
10. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology 2002;36:1273–1279. DOI: 10.1053/jhep.2002.36502
11. McHutchison JG, Lawitz EJ, Shiffman ML, et al. IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361(6): 580-93. DOI: 10.1056/NEJMoa0808010
12. Hézode, C, Fontaine, H, Dorival, C, et al. Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology 2014; 147: 132-142. DOI: 10.1053/j.gastro.2014.03.051
13. Reddy KR, Bruno S, Rossaro L, et al. Predictors of sustained virologic response among treatment-naïve patients with hepatitis C virus genotype 1 when treated with boceprevir (boc) plus peginterferon alfa-2b/rivabirin (PR). J Hepatol 2011; 54: S190.
DOI: https://doi.org/10.1016/S0016-5085(11)63910-3
14. Castera L, Forns X, Alberti A. Non-invasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48: 835–847. DOI: 10.1016/j.jhep.2008.02.008.
15. Efectividad diagnóstica y seguridad de la elastografía en el estudio de la fibrosis hepática en enfermedad hepática crónica. Informes de evaluación de tecnologías sanitarias [Diagnostic effectiveness and safety of elastography in the study of liver fibrosis in chronic liver disease. Health technology assessment reports]. Madrid: Ministerio de Sanidad, Consumo y Bienestar Social, 2008. [Accessed 10 Feb 2020]. Available from: http://gesdoc.isciii.es/gesdoccontroller?action=download&id=22/01/2019-b64a8919d0
16. Pavlov CS, Casazza G, Nikolova D et al. Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease. Cochrane Db Syst Rev 2015; 1: CD010542. DOI: 10.1002/14651858.CD010542.pub2.
17. Freeman AJ, Dore GJ, Law MG, et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. Hepatology 2001; 34: 809-16. DOI: 10.1053/jhep.2001.27831
18. Goñi Esarte S, Juanbeltz R, Martinez-Baz I, et al. Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. Rev Esp Enferm Dig 2019; 111: 445-52. DOI: 10.17235/reed.2019.6063/2018.
19. Crespo J, Lázaro de Mercado P, Blasco Bravo AJ, et al. Diagnosis of hepatitis C virus infection in Spain: An opportunity to improve. Enferm Infecc Microbiol Clin 2019; 37(4): 231-8. DOI: 10.1016/j.eimc.2018.05.016.
20. Peeling RW, Boeras DI, Marinucci F, et al. The future of viral hepatitis testing: Innovations in testing technologies and approaches. BMC Infect Dis 2017; 17(Suppl 1): 699. DOI: 10.1186/s12879-017-2775-0
21. Grebely J, Applegate TL, Cunningham P, et al. Hepatitis C point-of-care diagnostics: In search of a single visit diagnosis. Expert Rev Mol Diagn 2017; 17: 1109-5. DOI: 10.1080/14737159.2017.1400385
22. Assoumou SA, Tasillo A, Leff JA, et al. Cost-effectiveness of one-time hepatitis C screening strategies among adolescents and young adults in primary care settings. Clin Infect Dis 2018; 66: 376-84. DOI: 10.1093/cid/cix798
23. Chhatwal J. Hepatitis C screening: From modeling to public health policy. Clin Infect Dis 2018; 66: 385-6. DOI: 10.1093/cid/cix800
24. Kracht PAM, Arends JE, van Erpecum KJ, et al. Strategies for achieving viral hepatitis C micro-elimination in the Netherlands. Hepatol Med Policy 2018; 3: 12. DOI: 10.1186/s41124-018-0040-9.
25. Servicio Cántabro de Salud. Estrategia para la eliminación de la hepatitis C en Cantabria. [Strategy for the elimination of hepatitis C in Cantabria]. [Accessed 10 Feb 2020]. Available from: http://www.scsalud.es/documents/ 2162705/2529917/Hepatitis+C.pdf
26. Consejería de Sanidad. Dirección General de Coordinación de Atención al Ciudadano and Humanización de la Asistencia Sanitaria. Libro Blanco de la Hepatitis C en la Comunidad de Madrid 2016-2019. Edición: Julio 2017. . [Accessed 10 Feb 2020]. Available from: Disponible en: http://www.comunidad.madrid/publicacion/1354663261085
27. Kracht PAM, Arends JE, van Erpecum KJ, et al. Retrieval and cure of chronic hepatitis C (REACH): Results of microelimination in the Utrecht province. Liver Int 2019; 39(3): 455-62. DOI: 10.1111/liv.13959.
28. Sagnelli E, Alessio L, Sagnelli C, et al. Clinical findings of HCV chronic infection in undocumented immigrants and low-income refugees in the three areas of Southern Italy. Ann Hepatol 2018; 17(1): 47-53. DOI: 10.5604/01.3001.0010.7534.
29. Crespo J, Albillos A, Buti M, et al. Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH). Rev Esp Enferm Dig 2019;111(11):862-73. DOI: 10.17235/reed.2019.6700/2019.
Related articles

Original

Hepatitis C in homeless people: reaching a hard-to-reach population

DOI: 10.17235/reed.2021.7737/2020

Citation tools
Burgui C, Martín C, Juanbeltz R, San Miguel R, Martínez-Baz I, Zozaya J, et all. Recapture of patients with an incomplete diagnosis of hepatitis C virus infection. 6944/2020


Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Metrics
This article has received 789 visits.
This article has been downloaded 189 times.

Statistics from Dimensions


Statistics from Plum Analytics

Publication history

Received: 05/02/2020

Accepted: 18/04/2020

Online First: 09/06/2020

Published: 08/07/2020

Article revision time: 57 days

Article Online First time: 125 days

Article editing time: 154 days


Share
This article hasn't been rated yet.
Reader rating:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
The Spanish Journal of Gastroenterology is the official organ of the Sociedad Española de Patología Digestiva, the Sociedad Española de Endoscopia Digestiva and the Asociación Española de Ecografía Digestiva
Cookie policy Privacy Policy Legal Notice © Copyright 2023 y Creative Commons. The Spanish Journal of Gastroenterology